Jazz Pharmaceuticals reported a 10% year-over-year revenue increase to $1.2 billion in Q3 2026, driven by strong sales of Xywav, Zepzelca, and the newly launched Ziihera for HER2+ gastroesophageal cancer. The company also completed the acquisition of Actio Biosciences, adding a promising epilepsy drug to its pipeline. Jazz raised its full-year 2026 revenue guidance to $4.775-$4.85 billion, reflecting confidence in continued growth. Upcoming milestones include data presentations for new epilepsy treatments and ongoing clinical trials.
Jazz Pharmaceuticals reported a 10% revenue increase to $1.2 billion in Q3 2026, reflecting strong product sales and pipeline expansion. For readers following the health sector, here is Pluang's market snapshot as of Nov 03, 2026 04:11 WIB: out of 150 priced US health stocks, 48 rose and 100 fell. Notable movers include DNA at USD 9.81 with a 12.60% decline and a Pluang order activity of 44% Sell / 56% Buy, TWST at USD 152.02 down 12.36% with 18% Sell / 82% Buy, and TXG at USD 61.51 down 12.27% with 58% Sell / 42% Buy. Typical hold times range from 9 to 92 days.
Zentalis Pharmaceuticals awarded 136,000 non-qualified stock options to four newly hired employees as an inducement to join the company, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.85, matching the stock's closing p...
Dianthus Therapeutics, a clinical-stage biotech company, granted stock options to three new non-executive employees as inducements for joining the company. The options cover 26,000 shares at an exercise price of $82.25, vesting over four years. This ...
The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...
The FDA placed Bright Minds Biosciences' planned Phase 2 epilepsy trial for BMB-101 on partial clinical hold due to toxicity findings in mice and insufficient pharmacokinetic and juvenile-toxicity data. This action caused a sharp decline in the compa...
NVIDIA has published detailed implementation recipes for its Cosmos world models, enabling developers to create simulations for vehicles, robots, and surgical procedures. These recipes guide model adaptation, testing, and GPU deployment, supporting v...
